Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.

Hiddo J Lambers HeerspinkVlado PerkovicKatherine R Tuttle Pablo E PergolaKenneth W MahaffeyUptal D PatelJulie H IshidaAlbert KuoFang ChenRobert KustraVladimir Petrovic Ellen Burgess Naoki Kashihara Glenn M Chertow

Published in: Journal of the American Society of Nephrology : JASN (2024)

Selonsertib attenuated the decline in eGFRcr over up to 84 weeks; however, it resulted in a numerically higher number of patients reaching a kidney clinical event and a numerically higher rate of investigator-reported acute kidney injury.

Keyphrases

acute kidney injury
clinical trial
end stage renal disease
double blind
open label
ejection fraction
newly diagnosed
chronic kidney disease
phase ii
type diabetes
prognostic factors
cardiac surgery
randomized controlled trial
patient reported